Depression and Anxiety

• 

  Publication Venue For

  • Genetic variants in 5-HTTLPR, BDNF, HTR1A, COMT, and FKBP5 and risk for treated depression after cancer diagnosis..  34:845-855. 2017
  • PLASMA OXYTOCIN CONCENTRATION AND DEPRESSIVE SYMPTOMS: A REVIEW OF CURRENT EVIDENCE AND DIRECTIONS FOR FUTURE RESEARCH..  33:316-322. 2016
  • Intimate partner violence and new-onset depression: a longitudinal study of women's childhood and adult histories of abuse..  32:316-324. 2015
  • Symptom features of postpartum depression: are they distinct?.  25:20-26. 2008
  • A comparison of the SPRINT and CAPS assessment scales for posttraumatic stress disorder..  23:437-440. 2006
  • Multidimensional effects of sertraline in social anxiety disorder..  23:6-10. 2006
  • Naltrexone in patients with bipolar disorder and alcohol dependence..  23:492-495. 2006
  • Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting..  21:26-32. 2005
  • Impact of depressive symptoms on the treatment of generalized social anxiety disorder..  22:161-167. 2005
  • Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression..  20:114-122. 2004
  • Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study..  19:234-240. 2004
  • Posttraumatic stress disorder in callers to the Anxiety Disorders Association of America..  19:96-104. 2004
  • Social anxiety disorder in callers to the Anxiety Disorders Association of America..  20:101-106. 2004
  • Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC)..  18:76-82. 2003
  • Pregnancy anxiety and comorbid depression and anger: effects on the fetus and neonate..  17:140-151. 2003
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms..  16:4-13. 2002
  • Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials..  15:75-78. 2002
  • Facial expressions and EEG in infants of intrusive and withdrawn mothers with depressive symptoms..  15:10-17. 2002
  • Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder..  15:29-33. 2002
  • Naturalistic study of the early psychiatric use of citalopram in the United States..  16:121-127. 2002
  • Subcortical white matter lesions and functional impairment in geriatric depression..  15:23-28. 2002
  • Clinician-administered PTSD scale: a review of the first ten years of research..  13:132-156. 2001
  • Mini-SPIN: A brief screening assessment for generalized social anxiety disorder..  14:137-140. 2001
  • Paroxetine for social anxiety and alcohol use in dual-diagnosed patients..  14:255-262. 2001
  • Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS)..  12:178-187. 2000
  • Completeness of response and quality of life in mood and anxiety disorders..  12 Suppl 1:95-101. 2000
  • ECT and TMS: past, present, and future..  12:115-117. 2000
  • EEG effects of ECT: implications for rTMS..  12:157-165. 2000
  • Social anxiety disorder under scrutiny..  11:93-98. 2000
  • Further psychometric assessment of the TOP-8: a brief interview-based measure of PTSD..  9:135-137. 1999
  • Age of first onset of bipolar disorder: demographic, family history, and psychosocial correlates..  7:76-82. 1998
  • Fluoxetine in child and adolescent depression: acute and maintenance treatment..  7:32-39. 1998
  • Six-month outcomes for MRI-related vascular depression..  8:142-146. 1998
  • Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis..  6:10-18. 1997
  • Dexamethasone suppression test identifies a subset of elderly depressed patients with reduced platelet serotonin transport and resistance to imipramine inhibition of transport..  6:19-25. 1997
  • Prevalence of antithyroid antibodies in mood disorders.  5:91-96. 1997
  • Relationship between objective and subjective sleep measures in depressed patients and healthy controls..  5:97-102. 1997
  • Structured interview for PTSD (SIP): psychometric validation for DSM-IV criteria..  5:127-129. 1997
  • Decision model for the acute treatment of mania..  4:289-293. 1996